Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TACE with or without tislelizumab after curative resection for HCC with microvascular invasion
ChiCTR2600135819Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Recurrence-Free Survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600135819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135819.